A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and Female Schizophrenic Patients for Up to 28 Days.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs SB 773812 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- 12 Oct 2006 Status change
- 17 Dec 2005 New trial record.